Indication

Variegate porphyria

Variegate porphyria is a rare autosomal dominant acute hepatic porphyria caused by heterozygous pathogenic variants in the *PPOX* gene, leading to partial deficiency of the mitochondrial enzyme protoporphyrinogen oxidase. Read more about Variegate porphyria

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Variegate porphyria therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Variegate porphyria preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Variegate porphyria.

Variegate porphyria is a rare autosomal dominant acute hepatic porphyria caused by heterozygous pathogenic variants in the *PPOX* gene, leading to partial deficiency of the mitochondrial enzyme protoporphyrinogen oxidase.

This enzymatic defect disrupts the heme biosynthetic pathway, resulting in the systemic accumulation and increased excretion of photoreactive porphyrins and neurotoxic porphyrin precursors.

It characteristically manifests after puberty with cutaneous lesions, acute neurovisceral attacks, or a combination of both.

Defining cutaneous findings include sun-induced skin fragility, erosions, blistering bullae, and scarring, while acute neurovisceral episodes present with severe abdominal pain, peripheral neuropathy, autonomic dysfunction, and neuropsychiatric disturbances often triggered by specific medications, fasting, or hormonal shifts.

Personalize your experience

Follow Variegate porphyria and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it